Taro Pharma (TARO) Misses Q2 EPS by 36c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
Taro Provides Results for September 30, 2021
October 28, 2021 5:15 PM EDTHAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today provided unaudited financial results for the quarter and six months ended September 30, 2021.
Quarter ended September 30, 2021 Highlights compared to September 30, 2020
Net sales of $132.0 million decreased $10.9 million. Gross profit of $62.0 million (47.0% of net sales compared to 57.1%) decreased $19.5 million. Research and development (R&D) expenses of $12.5 million decreased $4.1 million. Selling, marketing, general and administrative expenses (SG&A) of $23.7 million were in line with the prior year quarter. Settlements and loss... More